260 related articles for article (PubMed ID: 22198185)
1. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
2. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
[TBL] [Abstract][Full Text] [Related]
4. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
5. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
[TBL] [Abstract][Full Text] [Related]
6. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation].
Zhou Z; Wang M; He Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
[TBL] [Abstract][Full Text] [Related]
9. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
[TBL] [Abstract][Full Text] [Related]
10. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
11. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
[TBL] [Abstract][Full Text] [Related]
13. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
14. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.
Keever-Taylor CA; Klein JP; Eastwood D; Bredeson C; Margolis DA; Burns WH; Vesole DH
Bone Marrow Transplant; 2001 Apr; 27(8):791-800. PubMed ID: 11477435
[TBL] [Abstract][Full Text] [Related]
16. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
17. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
18. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
[TBL] [Abstract][Full Text] [Related]
19. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
